Carmed Pharmaceuticals announced plans to expand its U.S. presence with an upcoming launch on Amazon, building on its entry into the United States market and representing the next step in making its research-driven botanical formulations more accessible to consumers through one of the world's largest online retail platforms. The company's approach integrates traditional botanical knowledge with modern pharmaceutical methodology to develop standardized formulations designed to support immune resilience, cellular health, and overall physiological balance.
The planned Amazon launch is designed to provide broader access to Carmed's formulations while supporting the company's long-term strategy of combining scientific development with scalable distribution. By leveraging Amazon's platform, Carmed aims to reach a wider audience seeking standardized, quality-controlled botanical formulations grounded in research and formulation science. "Amazon allows us to make our formulations more accessible while maintaining our focus on scientific integrity and standardization," said Mustafa Can, Founder of Carmed Pharmaceuticals.
As part of its Amazon launch, Carmed Pharmaceuticals plans to introduce several flagship formulations including Vacrol® Kids Spray for children ages 4-11, S-Mix® for immune function support, Vacrol® Capsule for microbial balance, Vacrol-M® Capsule for immune and respiratory wellness, and Omevaq-3® for cellular energy metabolism. Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified. According to the company, Carmed's formulations are developed using standardized processes designed to ensure consistency, reproducibility, and quality control across product batches.
Carmed's development model is supported by ongoing research and collaboration with academic institutions, laboratories, and medical researchers focused on formulation science and bioactive compound evaluation. In January 2026, a study published in the peer-reviewed journal Plants examined Vacrol® and S-Mix® in preclinical laboratory and in ovo models as part of broader scientific investigation into carvacrol-based formulations and multicomponent botanical interactions. The company emphasizes that such research reflects scientific investigation into botanical bioactivity and formulation design and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.
The company's U.S. strategy is centered on building long-term credibility through scientific rigor, regulatory alignment, and consistent product quality as it expands distribution. "The Amazon launch is an important step in making Carmed's formulations available to a broader audience in the United States," said Ceren Can, Global Brand Director of Carmed Pharmaceuticals. The Amazon launch represents a key milestone in that strategy, enabling broader consumer access while supporting continued investment in research and formulation development. Availability timelines and product listings on Amazon will be announced in the coming weeks. More information about the company's approach can be found at https://www.carmedpharmaceuticals.com.
